Figure 4.
Deleting senescent cells reduces AML tumor volume. (A) MN1 were grown on p16-3MR nonsenescent or senescent BMSC for 2 days with and without treatment with GCV (10 µg/mL) (n = 3). (B) GCV experiment in vivo. (C-D) 1 × 105 MN1-luc cells were injected into p16-3MR mice (n = 8 for each treatment group). Mice were imaged at 14 days postengraftment. At day 15, GCV (25 mg/kg) or PBS treatment was started for 5 days. Mice were then imaged again 1 day after GCV treatment had finished. (C) Pre and post images show the same mice in the same order. (D) Densitometry of the bioluminescent images was performed to determine differences between vehicle and GCV treated animals. (E-F) Kaplan-Meier survival curves for p16-3MR (n = 8) and C57BL/6 (n = 7) mice injected with MN1 and then treated with vehicle or GCV as shown in panel B.

Deleting senescent cells reduces AML tumor volume. (A) MN1 were grown on p16-3MR nonsenescent or senescent BMSC for 2 days with and without treatment with GCV (10 µg/mL) (n = 3). (B) GCV experiment in vivo. (C-D) 1 × 105 MN1-luc cells were injected into p16-3MR mice (n = 8 for each treatment group). Mice were imaged at 14 days postengraftment. At day 15, GCV (25 mg/kg) or PBS treatment was started for 5 days. Mice were then imaged again 1 day after GCV treatment had finished. (C) Pre and post images show the same mice in the same order. (D) Densitometry of the bioluminescent images was performed to determine differences between vehicle and GCV treated animals. (E-F) Kaplan-Meier survival curves for p16-3MR (n = 8) and C57BL/6 (n = 7) mice injected with MN1 and then treated with vehicle or GCV as shown in panel B.

Close Modal

or Create an Account

Close Modal
Close Modal